06/06/09
EAACI 2009: Stallergenes Symposiumon June 9th, 10:30 a.m
XXVIII Congress of the European Academy of Allergy and Clinical...
29/04/09
House dust mites desensitization tablets: Positive results from a phase IIb/III clinical trial
Release of the first year outcome of the VO 57.07 clinical study on a...
24/03/09
2008 : A strong performance
Strong growth in results, Sales up 16%, Net profit up 17%
Sound financial...
| We comply with the HONcode standard for trustworthy health information: verify here. |
Last update: 01/06/2009
Welcome on the corporate website of STALLERGENES
Stallergenes is an European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions.
The Group's activities focus on research into allergy, and the development, production and distribution of allergen extracts for the curative treatment of allergic rhinitis and asthma.
Visit the investors website
